As described in today’s issue of Smart Tech Investor, we are adding the three cancer-fighting companies described in our recent special report, “One Little Shot to Kill Cancer Dead“, to the new STI Special Situations Portfolio. Those stocks are Argos Therapeutics (ARGS), Juno Therapeutics (JUNO), and Ziopharm Oncology (ZIOP). Given the volatile nature of these type of stocks and their extreme upside potential, we do not provide buy limit of stop loss prices for them. We also recommend buying them all as a group to increase the probability of participating in the long term growth potential of this sector.

Also, the three exoskeleton stocks that have been held in the Medical Profits portfolio since being first recommended last June have been moved to the Special Situations portfolio to reflect their heightened risk/reward profile. They are Ekso Bionics (EKSO), ReWalk Robotics (RWLK), and Parker-Hannifin (PH).